Journal: Biomolecules & Therapeutics

Article Title: Design, Screening and Development of Asymmetric siRNAs Targeting the MYC Oncogene in Triple-Negative Breast Cancer

doi: 10.4062/biomolther.2024.071

Figure Lengend Snippet: Primers used for mRNA quantification by qPCR

Article Snippet: The following primary antibodies were used: recombinant anti-c-MYC antibody [Y69] (#ab32072, Abcam, Cambridge, MA, USA), anti-beta actin antibody (#ab8227, Abcam); anti-GAPDH antibody [EPR16891] as a loading control (#ab181602, Abcam), anti-RAD51 antibody ([EPR4030(3)] (#ab133534, Abcam), PARP1 (46D11) rabbit mAb (#9532, Cell Signaling Technology, Danvers, MA, USA) and RRM2 (E7Y9J) XP ® rabbit mAb (#65939, Cell Signaling Technology).

Techniques:

Journal: Biomolecules & Therapeutics

Article Title: Design, Screening and Development of Asymmetric siRNAs Targeting the MYC Oncogene in Triple-Negative Breast Cancer

doi: 10.4062/biomolther.2024.071

Figure Lengend Snippet: Mod_asiRNA10-6 was more efficient at downregulating MYC, RRM2, RAD51 and PARP1 than the other siRNAs. (A) The relative mRNA expression of MYC, (B) RRM2, (C) RAD51 and (D) PARP1 in the MDA-MB-231 cell line. (E) The viability of the MDA-MB-231 cell line. (F) The immunoblots of MYC, RRM2, RAD51 and PARP1 in MDA-MB-231 cells and (G) MDA-MB-157 cell lines. (H) The viability of MDA-MB-157 cell line. For the modification patterns of each asiRNA used, refer to and . The dose of all siRNAs was 20 nM. Scramble: negative control asiRNAs (stabilized by modifications similar to those of the target asiRNAs). The relative mRNA expression of MYC was normalized to that of the endogenous control, HPRT1. *** p <0.001, **** p <0.0001, and ns: nonsignificant. All the experiments were done in triplicate (n=3).

Article Snippet: The following primary antibodies were used: recombinant anti-c-MYC antibody [Y69] (#ab32072, Abcam, Cambridge, MA, USA), anti-beta actin antibody (#ab8227, Abcam); anti-GAPDH antibody [EPR16891] as a loading control (#ab181602, Abcam), anti-RAD51 antibody ([EPR4030(3)] (#ab133534, Abcam), PARP1 (46D11) rabbit mAb (#9532, Cell Signaling Technology, Danvers, MA, USA) and RRM2 (E7Y9J) XP ® rabbit mAb (#65939, Cell Signaling Technology).

Techniques: Expressing, Western Blot, Modification, Negative Control, Control

Journal: Cancers

Article Title: Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma

doi: 10.3390/cancers16051066

Figure Lengend Snippet: Differentially expressed proteins based on HPV status. ( a ) Normalized linear expression of RRPA data of CDKN2A, RRM2, and CDC25C depicted in a bar blot with false discovery rate (FDR) adjusted p -value given for each protein per data set. ( b ) Immunoblot of lysates for HPV+ (red bars) and HPV− (black bars) PDX models for RRM2, HPV16-E7, and GAPDH depicted. ( c ) Immunoblot of CDC25C and GAPDH. ( d ) Immunoblot of p16 and GAPDH. The uncropped blots are shown in File S1.

Article Snippet: Membranes were blotted with primary antibodies for RRM2 (1:1000, 65939S, Cell Signaling, Danvers, MA, USA); p16 (1:1000, 80772S, Cell Signaling); CDC25C (1:1000, 4688S, Cell Signaling); and HPV16-E7 (1:1000, GTX133411, GeneTex, Irvine, CA, USA) and a corresponding secondary antibody (1:2000 of Anti-rabbit IgG HRP linked, 7074P2, Cell Signaling or 1:2000 Anti-mouse IgG HRP linked, 7076S, Cell Signaling).

Techniques: Expressing, Western Blot